Barriers to Use of Fecal Microbiota Transplant in C. Diff Infection
A focused discussion on the barriers to fecal microbiota transplant for patients with clostridium difficile infection.
An Overview of Fecal Microbiota Transplant Use in C. Diff Infection
Experts focus on the current state of fecal microbiota transplant as a treatment option for clostridium difficile infection.
Challenges in the Management of C. Diff Infection
Panelists take a step back to consider the broader challenges in managing patients with clostridium difficile infection.
Payer Perspectives on Risk Stratification for CDI Recurrence
Payer participants consider how they proactively risk stratify patients for clostridium difficile infection recurrence.
Defining Value in Recurrent CDI
An overview on how the cost of therapy for recurrent clostridium difficile infection may impact treatment planning.
Practical Considerations for Fidaxomicin Use in Recurrent CDI
Focused discussion on the use of fidaxomicin for clostridium difficile infection, and possible barriers to the selection of this agent.
Payer Perspectives on Coverage Criteria for Clostridium Difficile Treatments
Payer participants break down how coverage criteria are determined for treatments for clostridium difficile infection.
Recurrent CDI: Risk Factors and Outcomes
Experts focus on recurrent clostridium difficile infection to define risk factors and discuss impact on patient outcomes.
Defining Traditional Risk Factors for Developing C. Diff Infection
Opening their discussion, panelists elucidate patient factors that may impact risk of developing clostridium difficile infection.
Cold Agglutinin Disease: Clinical Pearls
Take-aways from a discussion on the management of cold agglutinin disease, with expert insight on navigating the healthcare system to optimize patient care.
Implications for Using Complement Therapies for Cold Agglutinin Disease
Considerations regarding where newer, novel complement therapies will likely fit into the treatment landscape for patients with cold agglutinin disease.
Coverage for Complement Therapies for Cold Agglutinin Disease
Payers debate criteria for coverage of novel targeted therapies under investigation as use as novel complement therapy for cold agglutinin disease.
Novel Complement Therapies for Cold Agglutinin Disease
During a discussion on the next frontier of medicine for cold agglutinin disease, stakeholders react to the rationale for studying newer, novel complement-targeted therapies.
Cold Agglutinin Disease: Treatment Gaps
Payers react to gaps that impact coverage decisions for therapies available off-label for cold agglutinin disease.
Treating Cold Agglutinin Disease With Anti–B-Cell Therapy
Clinicians comment on their approaches when treating patients with cold agglutinin disease with an anti–B-cell therapy.
Coverage of Anti–B-Cell Therapies for Cold Agglutinin Disease
Criteria that support coverage decisions for anti–B-cell therapies for cold agglutinin disease, which are not currently FDA approved.
Anti–B-Cell Therapy for Cold Agglutinin Disease
The rationale for treating patients with cold agglutinin disease with anti–B-cell therapies such as rituximab, bortezomib, or daratumumab based on supporting data.
Cold Agglutinin Disease: Treatment Considerations
An overview of the roles of plasmapheresis, IVIG, transfusions, and corticosteroids as treatment for patients with cold agglutinin disease.
Educating Patients and HCPs About Cold Agglutinin Disease
Special considerations educating health care professionals and patients about lifestyle interventions and cold avoidance for cold agglutinin disease.
Challenges Managing Cold Agglutinin Disease
A panel of clinicians and payers highlight challenges that impact the treatment of a rare autoimmune hemolytic anemia, cold agglutinin disease.
PRO Data & Support for Patients With Cold Agglutinin Disease
Payer considerations regarding the measurement of treatment outcomes for patients with cold agglutinin disease, and resources available to help support patients through their care continuum.
Cold Agglutinin Disease: Treatment Goals
Clinicians offer their perspectives on establishing treatment goals for patients with cold agglutinin disease and describe how they measure treatment response.
Cold Agglutinin Disease: A Differential Diagnosis
Diagnostic criteria used by health care professionals who manage patients with autoimmune hemolytic anemias to help distinguish cold agglutinin disease from other medical conditions.
Cold Agglutinin Disease: Impact on Health Care Utilization
Payers comment on main drivers of health care utilization among patients with cold agglutinin disease.
Impact of Cold Agglutinin Disease on Patients
Health care professionals who treat patients with cold agglutinin disease, a rare autoimmune hemolytic anemia, comment on symptoms that make the condition difficult to diagnose and remark on the burden on patients.
Types of Autoimmune Hemolytic Anemias
Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias.
An Overview of Cold Agglutinin Disease
Jeremy Lorber, MD, explains what is known about the pathophysiology of a rare autoimmune hemolytic anemia, cold agglutinin disease.
Future of Cardiorenal Metabolic Syndrome Management
Jeffrey Turner, MD; Nihar R. Desai, MD, MPH; and Om P. Ganda, MD, provide closing thoughts on the future of cardiorenal metabolic syndrome management.
Improving Uptake of SGLT2 Inhibitors for Cardiorenal Metabolic Syndrome
Expert physicians discuss the underutilization of SGLT2 inhibitors and strategies to improve uptake in patients with cardiorenal metabolic syndrome.
Role of Quality Measures in Population Health Management of Cardiorenal Metabolic Syndrome
Neil Minkoff, MD, and Nihar R. Desai, MD, MPH, provide insight into quality measures to incentivize value-based care in cardiorenal metabolic syndrome.
